DrugPatentWatch Database Preview

Details for Patent: 8,227,471

« Back to Dashboard

Which drugs does patent 8,227,471 protect, and when does it expire?

Patent 8,227,471 protects ADDYI and is included in one NDA.

This patent has forty-two patent family members in twenty-nine countries.

Summary for Patent: 8,227,471

Title:	Treating sexual desire disorders with flibanserin
Abstract:	The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
Inventor(s):	Borsini; Franco (Bad Waldsee, DE), Evans; Kenneth Robert (Toronto, CA)
Assignee:	Sprout Pharmaceuticals, Inc. (Raleigh, NC)
Application Number:	11/524,268
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,227,471

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015		RX	Yes	Yes						USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

Foreign Priority and PCT Information for Patent: 8,227,471

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	01125020	Oct 20, 2001

International Family Members for US Patent 8,227,471

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	037109
Argentina	077480
Austria	327757
Australia	2002333894